摘要
目的研究依达拉奉与巴曲酶联用在脑梗死治疗中的疗效。方法120例脑梗死的患者分为联用组(巴曲酶加依达拉奉),依达拉奉组,巴曲酶组和对照组,每组30例。观察治疗后神经功能改善情况及血浆纤维蛋白原(F IB)的变化。结果联用组治疗后各时期ESS评分均显著高于对照组(P<0.05),21d及90d显著高于巴曲酶组和依达拉奉组(P<0.05);联用组的显效率在90d显著高于其它各组(P<0.05),21d后有效率显著高于其它组(P<0.05);联用组及巴曲酶组治疗后血浆纤维蛋白原含量显著降低(P<0.01)。结论依达拉奉与巴曲酶联用能显著提高脑梗死患者的疗效。
Objective To evaluate the character and effect of edaravone combined with batroxobin in treatment of cerebral infarction. Methods 120 patients suffered with cerebral infarction were divided into combined group （edaravone with batroxobin）,batroxobin group,edaravone group and control group. Each group had 30 patients. Changes of neural function and FIB content were studied. Results The ESS grade of combined group was significantly higher than that of control group after treatment（P〈0. 05）. On 21d and 90d after treatment it was significantly higher than those of edaravone and batroxobin group（P〈0.05）. The significant effect rate of combined group were significantly higher than which of other groups on 90d （P〈0.05）. The efficient rate of combined group was significantly higher than those of other groups after 21 days of treatment （P〈0.05）. Contends of FIB in combined group and batroxobin group were significantly decreased after treatment （P〈0.01）. Conclusion Edaravone combined with Batroxobin can notably and safely improve the symptom of cerebral infarction patients.
出处
《中风与神经疾病杂志》
CAS
CSCD
北大核心
2006年第3期328-330,共3页
Journal of Apoplexy and Nervous Diseases
关键词
依达拉奉
巴曲酶
脑梗死
疗效
Edaravone
Batroxobin
Cerebral infarction
Effect
